LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Jegathisawaran, Jathishinie"
  2. AU="Inoue, Fumitaka"
  3. AU="Moore, Duncan T"
  4. AU="van Leeuwen, Nikki"
  5. AU="Anthony, James"
  6. AU="Abakay, Osman"
  7. AU="Ripà, Paola"
  8. AU="Harvey, P J"
  9. AU="Chopra, Jyoti"
  10. AU="Felitti, V. J."
  11. AU=Bleasel Martin D AU=Bleasel Martin D
  12. AU="Singh, Vimal Shankar"
  13. AU="Zanzottera, Milena"
  14. AU="Gössl, Mario"
  15. AU=Marshall Keri
  16. AU="Nava, M"
  17. AU="Banville, Allyson C"
  18. AU="Riethmuller, Didier"
  19. AU="Schoenbaechler, Valérie"
  20. AU="Liu, Shaohui"
  21. AU="Wennen, Myrte"

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Cost-effectiveness of Intermittent vs Continuous Pulse Oximetry Monitoring in Infants Hospitalized With Stabilized Bronchiolitis.

    Moretti, Myla E / Jegathisawaran, Jathishinie / Wahi, Gita / Bayliss, Ann / Kanani, Ronik / Pound, Catherine M / Sakran, Mahmoud / Parkin, Patricia C / Mahant, Sanjay

    JAMA network open

    2022  Volume 5, Issue 11, Page(s) e2243609

    Abstract: Importance: Pulse oximetry is a noninvasive technology that is integral to the supportive care of hospitalized infants with bronchiolitis. A multicenter, randomized trial comparing the effectiveness of intermittent vs continuous pulse oximetry found ... ...

    Abstract Importance: Pulse oximetry is a noninvasive technology that is integral to the supportive care of hospitalized infants with bronchiolitis. A multicenter, randomized trial comparing the effectiveness of intermittent vs continuous pulse oximetry found similar length of hospital stay and safety outcomes, and greater nursing satisfaction, with intermittent monitoring.
    Objectives: To evaluate the cost-effectiveness of intermittent vs continuous pulse oximetry in hospitalized infants with stabilized bronchiolitis.
    Design, setting, and participants: An economic evaluation concurrent with a randomized trial in community and tertiary children's hospitals in Ontario, Canada, was conducted using a probabilistic analysis. Patients were enrolled from November 1, 2016, to May 31, 2019. Data included infants aged 4 weeks to 24 months hospitalized with bronchiolitis, with or without supplemental oxygen, after stabilization. The cost-effectiveness analysis adopted a societal and health care system perspective and a time horizon from hospitalization to 15 days post-discharge. Patient level direct health care costs and indirect costs were included. Health resource use, costs, and clinical outcomes were obtained from trial data. Publicly available pricing resources were used to supplement costs. Ranges for sensitivity analysis were based on 95% confidence intervals of the trial data. All costs were reported in 2021 Canadian dollars.
    Interventions: Intermittent (every 4 hours) vs continuous pulse oximetry using an oxygen saturation target of 90% or higher.
    Main outcomes and measures: Costs and incremental costs.
    Results: Trial data from 229 infants (median [IQR] age, 4.0 [2.2-8.5] months; 136 boys [59.4%], 93 girls [40.6%]) were included. Mean societal costs per patient were $6879 (95% CI, $3393 to $12 317) in the intermittent and $7428 (95% CI, $1743 to $25 011) in the continuous group with a mean incremental cost of -$548 (95% CI, -$18 486 to $8105). Mean health care system costs per patient were $4195 (95% CI, $1191 to $9461) in the intermittent and $4716 (95% CI, $335 to $22 093) in the continuous group (incremental cost, -$520; 95% CI, -$18 286 to $7358). The mean effect measure of length of stay was similar between the 2 groups: 37.4 hours (95% CI, 1.0 to 137.7 hours) in the intermittent group and 38.5 hours (95% CI, 0 to 237.1 hours) in the continuous group. One-way sensitivity analyses on all variables revealed that the findings were robust and the incremental costs were not sensitive to the uncertainty within the defined ranges.
    Conclusions and relevance: In this prospective economic evaluation study, we found that costs were similar for intermittent and continuous pulse oximetry considering societal and health care perspectives. Given that clinical outcomes between monitoring strategies are comparable and that other practice considerations favor intermittent monitoring, these findings provide additional information that support the use of intermittent monitoring in hospitalized infants with stabilized bronchiolitis.
    MeSH term(s) Infant ; Male ; Female ; Child ; Humans ; Child, Preschool ; Cost-Benefit Analysis ; Prospective Studies ; Aftercare ; Patient Discharge ; Oximetry ; Bronchiolitis/diagnosis ; Bronchiolitis/therapy ; Hospitalization ; Ontario
    Language English
    Publishing date 2022-11-01
    Publishing country United States
    Document type Randomized Controlled Trial ; Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2022.43609
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Determining accurate costs for genomic sequencing technologies-a necessary prerequisite.

    Jegathisawaran, Jathishinie / Tsiplova, Kate / Hayeems, Robin / Ungar, Wendy J

    Journal of community genetics

    2019  Volume 11, Issue 2, Page(s) 235–238

    Abstract: Genome sequencing (GS) is increasingly being translated into clinical practice and is a technology characterized by a complex multi-step workflow. Funding decisions for GS would be aided by formal economic evaluation of GS platforms, but these analyses ... ...

    Abstract Genome sequencing (GS) is increasingly being translated into clinical practice and is a technology characterized by a complex multi-step workflow. Funding decisions for GS would be aided by formal economic evaluation of GS platforms, but these analyses require detailed costing. This article addresses the importance of and challenges associated with costing GS using a GS microcosting project in autism spectrum disorder as an illustrative example.
    Language English
    Publishing date 2019-11-15
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2543127-4
    ISSN 1868-6001 ; 1868-310X
    ISSN (online) 1868-6001
    ISSN 1868-310X
    DOI 10.1007/s12687-019-00442-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review.

    Jegathisawaran, Jathishinie / Holbrook, Anne / Bowen, James M / Burke, Natasha / Campbell, Kaitryn / Tarride, Jean-Eric

    Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique

    2017  Volume 24, Issue 2, Page(s) e1–e20

    Abstract: Objectives: The introduction of new oral anticoagulants for the prevention of stroke in atrial fibrillation (AF) has changed the clinical management of AF. To inform decision making around dabigatran by identifying factors influencing cost-effectiveness ...

    Abstract Objectives: The introduction of new oral anticoagulants for the prevention of stroke in atrial fibrillation (AF) has changed the clinical management of AF. To inform decision making around dabigatran by identifying factors influencing cost-effectiveness results, we undertook a systematic review of economic evaluations of dabigatran versus warfarin for the prevention of stroke in AF patients.
    Methods: A systematic literature search of Ovid Medline and Embase, Wiley's Cochrane Library, HEED, PubMed databases and grey literature was carried out for primary economic evaluations comparing dabigatran versus warfarin in patients with AF. Data on study characteristics, model inputs and results, and sensitivity analyses were abstracted and synthesized qualitatively.
    Results: Twenty-three economic evaluations were identified and RE-LY was cited in 52% of studies as the source of the efficacy data. Twenty evaluations used Markov modelling, 2 performed discrete event simulation, and 1 was a trial-based evaluation. Eighty-two percent reported base case incremental cost-effectiveness ratios (ICERs) of less than $50,000 USD/QALY. Key variables, including international normalized ratio (INR) control, the cost of monitoring, risk of stroke and bleeding, and age were found to alter the conclusions in only a few studies. Less commonly explored factors included time horizon and cost of long-term care follow-up.
    Conclusions: Several factors should be considered when interpreting the results of economic analyses which are based on randomized clinical trial evidence. Real-world data are needed to further assess the clinical and economic consequences of dabigatran relative to warfarin for the prevention of stroke in AF.
    MeSH term(s) Anticoagulants/economics ; Anticoagulants/therapeutic use ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/economics ; Cost-Benefit Analysis/methods ; Dabigatran/economics ; Dabigatran/therapeutic use ; Humans ; Randomized Controlled Trials as Topic/economics ; Randomized Controlled Trials as Topic/methods ; Stroke/economics ; Stroke/prevention & control ; Warfarin/economics ; Warfarin/therapeutic use
    Chemical Substances Anticoagulants ; Warfarin (5Q7ZVV76EI) ; Dabigatran (I0VM4M70GC)
    Language English
    Publishing date 2017-05-02
    Publishing country Australia
    Document type Journal Article ; Review ; Systematic Review
    ISSN 2561-8741
    ISSN (online) 2561-8741
    DOI 10.22374/1710-6222.24.2.1710
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Trio genome sequencing for developmental delay and pediatric heart conditions: A comparative microcost analysis.

    Jegathisawaran, Jathishinie / Tsiplova, Kate / Hayeems, Robin Z / Marshall, Christian R / Stavropoulos, Dimitri J / Pereira, Sergio L / Thiruvahindrapuram, Bhooma / Liston, Eriskay / Reuter, Miriam S / Manshaei, Roozbeh / Cohn, Iris / Jobling, Rebekah / Kim, Raymond H / Mital, Seema / Ungar, Wendy J

    Genetics in medicine : official journal of the American College of Medical Genetics

    2022  Volume 24, Issue 5, Page(s) 1027–1036

    Abstract: Purpose: Genome sequencing (GS) can aid clinical management of multiple pediatric conditions. Insurers require accurate cost information to inform funding and implementation decisions. The objective was to compare the laboratory workflows and microcosts ...

    Abstract Purpose: Genome sequencing (GS) can aid clinical management of multiple pediatric conditions. Insurers require accurate cost information to inform funding and implementation decisions. The objective was to compare the laboratory workflows and microcosts of trio GS testing in children with developmental delay (DD) and in children with cardiac conditions.
    Methods: Cost items related to each step in trio GS (child and 2 parents) for both populations were identified and measured. Program costs over 5 years were estimated. Probabilistic and deterministic analyses were conducted.
    Results: The mean cost per trio GS was CAD$6634.11 (95% CI = 6352.29-6913.40) for DD and CAD$8053.10 (95% CI = 7699.30-8558.10) for cardiac conditions. The 5-year program cost was CAD$28.11 million (95% CI = 26.91-29.29) for DD and CAD$5.63 million (95% CI = 5.38-5.98) for cardiac conditions. Supplies constituted the largest cost component for both populations. The higher cost per sample for the population with cardiac conditions was due to the inclusion of pharmacogenomics, higher bioinformatics labor costs, and a more labor intensive case review.
    Conclusion: This analysis indicated important variation in trio GS workflow and costs between pediatric populations in a single institution. Enhanced understanding of the clinical utility and costs of GS can inform harmonization and implementation decision-making.
    MeSH term(s) Base Sequence ; Child ; Chromosome Mapping ; Humans ; Parents ; Pharmacogenetics
    Language English
    Publishing date 2022-02-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1455352-1
    ISSN 1530-0366 ; 1098-3600
    ISSN (online) 1530-0366
    ISSN 1098-3600
    DOI 10.1016/j.gim.2022.01.020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Economic burden of illness associated with diabetic foot ulcers in Canada.

    Hopkins, Robert B / Burke, Natasha / Harlock, John / Jegathisawaran, Jathishinie / Goeree, Ron

    BMC health services research

    2015  Volume 15, Page(s) 13

    Abstract: Background: The primary objective was to estimate the national burden of illness in Canada for diabetic foot ulcer (DFU) for 2011. Secondary objectives included estimating the national incidence and prevalence of DFU, and the 3-year average cost for DFU ...

    Abstract Background: The primary objective was to estimate the national burden of illness in Canada for diabetic foot ulcer (DFU) for 2011. Secondary objectives included estimating the national incidence and prevalence of DFU, and the 3-year average cost for DFU incident cases.
    Methods: Analyses were conducted using four national databases for the period April 1, 2006 to March 31, 2011, with cases being identified by ICD-10 CA codes. Resource utilization and costs, expressed in 2011 Canadian dollars, were estimated for DFU-related hospitalizations, emergency care (ER), same day surgeries, home care, long term care, physician visits and caregiver time losses.
    Results: In Canada in the year 2011, DFU was associated with 16,883 hospital admissions (327,140 days), 31,095 ER or clinic visits, 41,367 rehabilitation clinic visits, and 26,493 interventions, including 6,036 amputations and 5,796 surgical debridements. This acute institution care represented $320.5 M, and with an additional $125.4 M for home care and $63.1 M for long term care, the annual cost associated with DFU-related care was $547.0 M, or $21,371 annual cost per prevalent case. In 2011, the national prevalence of DFU was 25,597 cases (75.1 per 100,000 population), consisting of 16,161 men (63.1%) and 9,436 women (36.9%), and an estimated 14,449 incident cases. For an incident case of DFU, the average 3-year cumulative cost was $52,360.
    Conclusion: The annual burden for DFU cases that have at least one admission or ER/clinic visit over a 5 year period is higher than previously reported.
    MeSH term(s) Aged ; Amputation/economics ; Amputation/statistics & numerical data ; Canada/epidemiology ; Cost of Illness ; Diabetic Foot/economics ; Diabetic Foot/epidemiology ; Epidemiologic Methods ; Female ; Health Resources/economics ; Health Resources/utilization ; Home Care Services/economics ; Home Care Services/statistics & numerical data ; Hospitalization/economics ; Hospitalization/statistics & numerical data ; Humans ; International Classification of Diseases ; Long-Term Care/economics ; Long-Term Care/statistics & numerical data ; Male
    Language English
    Publishing date 2015-01-22
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1472-6963
    ISSN (online) 1472-6963
    DOI 10.1186/s12913-015-0687-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Do different decision-analytic modeling approaches produce different results? A systematic review of cross-validation studies.

    Tsoi, Bernice / Goeree, Ron / Jegathisawaran, Jathishinie / Tarride, Jean-Eric / Blackhouse, Gord / O'Reilly, Daria

    Expert review of pharmacoeconomics & outcomes research

    2015  Volume 15, Issue 3, Page(s) 451–463

    Abstract: When choosing a modeling approach for health economic evaluation, certain criteria are often considered (e.g., population resolution, interactivity, time advancement mechanism, resource constraints). However, whether these criteria and their associated ... ...

    Abstract When choosing a modeling approach for health economic evaluation, certain criteria are often considered (e.g., population resolution, interactivity, time advancement mechanism, resource constraints). However, whether these criteria and their associated modeling approach impacts results remain poorly understood. A systematic review was conducted to identify cross-validation studies (i.e., modeling a problem using different approaches with the same body of evidence) to offer insight on this topic. With respect to population resolution, reviewed studies suggested that both aggregate- and individual-level models will generate comparable results, although a practical trade-off exists between validity and feasibility. In terms of interactivity, infectious-disease models consistently showed that, depending on the assumptions regarding probability of disease exposure, dynamic and static models may produce dissimilar results with opposing policy recommendations. Empirical evidence on the remaining criteria is limited. Greater discussion will therefore be necessary to promote a deeper understanding of the benefits and limits to each modeling approach.
    MeSH term(s) Communicable Diseases/economics ; Communicable Diseases/epidemiology ; Decision Support Techniques ; Health Policy ; Humans ; Models, Economic ; Validation Studies as Topic
    Language English
    Publishing date 2015-06
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2208481-2
    ISSN 1744-8379 ; 1473-7167
    ISSN (online) 1744-8379
    ISSN 1473-7167
    DOI 10.1586/14737167.2015.1021336
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Management of Hospital Formularies in Ontario: Challenges within a Local Health Integration Network.

    Burke, Natasha / Bowen, James M / Troyan, Sue / Jegathisawaran, Jathishinie / Gosse, Carolyn / Tonkin, Marita / Kagoma, Sandra / Goeree, Ron / Holbrook, Anne

    The Canadian journal of hospital pharmacy

    2016  Volume 69, Issue 3, Page(s) 187–193

    Abstract: Background: Expenditures on drugs dispensed and administered to patients in Canadian hospitals have been estimated at $2.4 billion per year. Pharmacy and therapeutics (P&T) committees play a key role in the evaluation and management of drug therapies in ...

    Abstract Background: Expenditures on drugs dispensed and administered to patients in Canadian hospitals have been estimated at $2.4 billion per year. Pharmacy and therapeutics (P&T) committees play a key role in the evaluation and management of drug therapies in this setting. Hospitals differ with respect to the composition of these committees, their members' expertise, and the processes used for making formulary decisions.
    Objectives: To examine the current processes for formulary drug review from the perspective of P&T committees and their individual members, and to examine the needs and preferences of these stakeholders related to evidence review and potential collaborative drug review processes within a large Local Health Integration Network (LHIN) in Ontario.
    Methods: Twenty-three sites within 10 hospital corporations in LHIN 4 (Hamilton Niagara Haldimand Brant) were recruited. A 2-part questionnaire was developed and pretested for clarity and comprehensiveness. The institution profile section of the questionnaire was to be completed by pharmacy directors and the P&T section by committee members.
    Results: Ten pharmacy directors and 28 committee members representing 10 P&T committees responded. A mean of 6.4 new drug requests were reviewed annually by each P&T committee. Across the LHIN, the workload associated with reviewing submissions for new drugs to be added to the formulary represented 0.84 full-time equivalent. The quality of clinical evidence in the drug submissions was rated more favourably than the quality of economic evidence; furthermore, the use of economic evidence was limited by a lack of health economics expertise within the committees. A centralized review process for the LHIN was perceived as beneficial to improve efficiency, the quality of review, and standardization, and also to reduce costs.
    Conclusions: Across the Hamilton Niagara Haldimand Brant LHIN, considerable time and resources are spent on the review of potential new drugs for addition to the hospitals' formularies. A standardized formulary review process, with greater use of provincial and national drug reviews, would likely benefit all LHINs.
    Language English
    Publishing date 2016-06-30
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 413450-3
    ISSN 1920-2903 ; 0008-4123
    ISSN (online) 1920-2903
    ISSN 0008-4123
    DOI 10.4212/cjhp.v69i3.1554
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top